- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.08. | RedChip Companies, Inc.: Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution | 575 | ACCESS Newswire | CEO James Foster to discuss the Company's financial and strategic position, commercial strategy for ImmuneSelect and development plans for ViraxImmuneWebinar to include an overview of recent corporate... ► Artikel lesen | |
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 18.08. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.08. | RedChip Companies, Inc.: Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV | 900 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small... ► Artikel lesen | |
| 31.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.07. | RedChip Companies, Inc.: Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 1.265 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / July 20, 2026 / RedChip Companies aired interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Virax Biolabs Group Ltd. (Nasdaq:VRAX) on the RedChip Small... ► Artikel lesen | |
| 16.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.07. | Virax BioLabs Group Limited: Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement | 382 | PR Newswire | Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 million... ► Artikel lesen | |
| 09.07. | Virax Biolabs Stock Skyrockets 100% on Exclusive Distribution Agreement | 5 | Barchart.com | ||
| 09.07. | Virax Biolabs secures $3.3m from warrant exercise | 2 | Investing.com | ||
| 09.07. | Virax Biolabs sichert sich 3,3 Mio. US-Dollar durch Ausübung von Optionen | 11 | Investing.com Deutsch | ||
| 09.07. | Virax Biolabs Stock Soars 246% On Exclusive Southeast Asia Supply Deal | 6 | RTTNews | ||
| 09.07. | Why Did Virax Biolabs Stock Triple In One Session? | 3 | Benzinga.com | ||
| 09.07. | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | 1.035 | AFX News | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 09.07. | Virax Biolabs signs supply deal with Fosun Diagnostics | 4 | Investing.com | ||
| 09.07. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 03.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 24.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.06. | Virax Biolabs Group announces 1-for-25 share consolidation | 3 | Seeking Alpha | ||
| 24.06. | Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation | 324 | PR Newswire | LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,35 | -0,11 % | BioNTech-Aktie: Septembertermin rückt in den Mittelpunkt | Für die BioNTech-Aktie rückt der Septembertermin in den Mittelpunkt: Auf einem internationalen Lungenkrebs-Kongress will der Mainzer Konzern erstmals globale Daten zur Kombination von Pumitamig und... ► Artikel lesen | |
| EVOTEC | 3,274 | -0,97 % | Kursexplosion wie bei Moderna? Übernahmekandidaten Evotec, Valneva und Vidac Pharma im Check! Analysten bullisch! | Moderna hat den Biotech-Markt mit dem Durchbruch bei der Bekämpfung von Hautkrebs wachgerüttelt. Partner Merck kommt in der Berichterstattung etwas zu kurz. Dabei bereitet sich der Pharmariese auf das... ► Artikel lesen | |
| MODERNA | 127,88 | -0,14 % | Moderna stockt Wandelanleihe auf bis zu 3 Milliarden Dollar auf | Moderna hat die erst am Vortag angekündigte Wandelanleihe aufgrund der Nachfrage deutlich größer dimensioniert. Statt der zunächst geplanten 2,0 Milliarden Dollar platziert der Biotechkonzern nun unverzinsliche... ► Artikel lesen | |
| VALNEVA | 2,999 | +0,77 % | Valneva mit Rückenwind: Analysten sehen über +150% Kurspotenzial | ||
| NOVAVAX | 8,870 | -0,22 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 193,08 | +0,03 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| ILLUMINA | 187,28 | -1,76 % | TRADING UPDATES: Novacyt's strikes Illumina deal; Beeks' Thailand deal | ||
| CRISPR THERAPEUTICS | 48,530 | -0,08 % | 2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 | ||
| VIKING THERAPEUTICS | 29,300 | +0,17 % | 3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong | ||
| INFLARX | 1,918 | +0,21 % | InflaRx im Fokus: Biotech-Pionier auf dem Weg zum medizinischen Durchbruch | ||
| VIVORYON THERAPEUTICS | 1,120 | +0,90 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,416 | +5,05 % | NurExone Biologic: Verändern ihre Super-Exosomen die Medizin?! | ||
| EXELIXIS | 51,03 | +0,33 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 19,360 | -2,12 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| ARBUTUS BIOPHARMA | 4,390 | -0,23 % | Arbutus Biopharma Corporation: Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,560 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.